Markets

Why Shares of Pacific Biosciences of California Plunged 23% Today

Shares of gene sequencing company plunged 23% in midday trading on Thursday after the company reported earnings that underwhelmed investors.

What: Shares of gene sequencing company Pacific Biosciences of California plunged 23% in midday trading on Thursday after the company reported earnings that underwhelmed investors.

So what: Fourth-quarter revenue surged 115% to $36.3 million on the back of a $20 million contractual milestone payment from Roche. But that still fell short of the $38.4 million in revenue that analysts expected. On the bottom line, net loss improved from $19.0 million a year ago to a $1.4 million loss, or $0.02 per share, which met expectations.

The bigger news may be that Pacific Biosciences announced it will sell as much as $30 million in shares on the open market, causing further dilution to shareholders.

Now what: Pacific Biosciences is in the midst of transitioning to a new product called the Sequel System that was launched in Q4 and that makes making or meeting estimates tough. Management said initial demand for Sequel has been strong, but it's going to ramp up slowly in 2016 so it has a smooth launch. That could be part of the disappointment today, with investors expecting a quicker ramp.

I don't think the fundamental story for Pacific Biosciences has changed, but there's uncertainty about when the company may see a lot of revenue growth and when that may lead to breakeven cash flow. And that's not uncertainty investors are willing to buy today.

The next billion-dollar iSecret

The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .

The article Why Shares of Pacific Biosciences of California Plunged 23% Today originally appeared on Fool.com.

Travis Hoium has no position in any stocks mentioned. The Motley Fool recommends Pacific Biosciences of California. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .

Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PACB

Other Topics

Stocks

Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More